Oncology Flashcards
Leukemia
- Proliferation of Lymphoid/Myeloid –>
a. Blasts (immature cells with punched out nuclei) in acute, while mature in chronic setting
b. Bone marrow involvement is > 20% –> pancytopenias
c. Blood spillage of WBC –> inc. TLC
leukeMoid reaction
cMl v/s acute inflammatory reaction:
- Both have inc. TLC count with Neutrophilia and left shift i.e. Bands
- LR has inc. LAP score
- CML has t(9;22 BCR-ABL) mutation and Basophilia with low LAP score.
Hodgkin’s Lymphoma
- EBV
- CD20 -ive, but B cell origin of Reed Sternberg cells. can lead to fibrosis due to cytokines leak.
- No leukemia phase
- CD15, CD30 +ive
- A lymphocytic mix can cause IL5 –> Eosinophilia.
Non-Hodgkin’s Lymphoma
- CD20 +ive, CD30-, CD15-, B cell origin except for Adult - T Cell leukemia/lymphoma and T-ALL (Acute Lymphoblastic Lymphoma)
- HIV and Autoimmune association
- Can occur leukemia phase
Myelophthisic anemia v/s Pancytopenias
Metastasis, fibrosis, TB —> Bone marrow invasion —> Leuko-erythroblastosis i.e. immature Granulocytes with left shift plus reticulocytes of a teardrop shape.
Aplastic anemia or pancytopenias do not give Leuko-erythroblastosis.
Lymphoma
- only lymphoid lineage is involved sparing myeloid cells
2. Reticuloendothelial system is involved sparing blood.
Non-Hodgkin’s Lymphoma (size and type)
- Small cell –> Folliculo Man-Co Mar
- Intermediate –> Burkitt
- Large –> DLBCL
Follicular Lymphoma
- CD20 +
- t(14;18) –> Translocation of heavy chain Ig @ 14 to BCL-2 site @ 18 –> overexpression of BCL-2 –>overstabalization of mitochondrial memb –> no cytochrome C release –> No apoptosis.
- Rx: Ritux –> CD20 antibody
- Reactive V/S follicular lumphoma:
a. Destruction of normal LN architecture
b. NO tingible macrophages
c. Monoclonality
Mantle (corona region) Lymphoma
- CD 20+
- t(11;14) –>Translocation of heavy chain Ig @ 14 to Cyclin D1 site @ 11 –> increase in promotion of G1 to S phase of cells
- CD 5+
- This is Mantle Co so coexpress CD 20 and CD 5 to gather
Marginal zone lymphoma
- CD 20+
- Linked to chronic inflammation
- eg. MALToma
Burkitt Lymphoma
- CD20+, asso. with EBV
- t(8;14) –> Translocation of heavy chain Ig @ 14 to c-myc site @ 8 –> c-myc is a transcription activator. other mutaions are t(8;2), t(8;22)
- African type involve jaw
- Sporadic type involve abdomen
- Starry sky appearance –> Lymphocytes with interspaced macrophages.
n-myc mutations are in
- Neuroblastoma
2. Small cell carcinoma of lung
DLBCL
- CD 20+
2. most common
AML (Acute Myeloblastic Leukemia)
- Acute –> Acute clinical picture
- Myeloblasts > 20% in bone marrow
- MPO (Myeloperoxidase) + in cytoplasm –> Auer rods
- Myelodysplastic syndrome is a risk factor
AML - M3 type
Acute Pro-Myeloblastic Leukemia
- t(15;17) –> Retinoic Acid Receptor (RAR) fussion —> Mal maturation —> Blasts accumulation
- Have Auer rods
- cause DIC
- Rx: Tretinoin i.e. All Trans-Retinoic Acid (ATRA)
AML - M5 type
Acute Monoblastic Leukemia
1. Give gum hypertrophy
AML - M7 type
Acute Megakaryoblastic Leukemia
- Exclusively lacks MPO
- Asso with Down Syndrome < age 5 years.
ALL (Acute Lymphoblastic Leukemia)
- Lymphoblasts > 20% in bone marrow
- tDt+
- Asso with Down syndrome > age 5 years
B-ALL
- tDt +
- CD 10-20 +
- t(12;21) Good prognosis
- t(9;22) Bad prognosis
T-ALL
- tDt+
- CD 1-9 +
- Give mediastinal mass so we call it “Acute Lymphoblastic Lymphoma”
- Acco with Down, Patau, Ataxia telengectasia, Bloom, Fanconi
- May spread to CNS and testes.
Myeloproliferative Disorders.
- Chronic Myeloid Lineage Proliferation —> Inc TLC —> Hypercellular Bone marrow with neoplastic WBC involvement of Myeloid lineage —> Can give either Marrow fibrosis with pancytopenias OR transformation into Acute Leukemias
- Types:
a. Polycythemia vera
b. CML
c. Essential thrombocythemia
d. Myelofibrosis
Polycythemia Vera
- All 3 myeloid lineage cells increase while most prominent are RBCs
- JAK-2 Kinase mutation
- Hyperviscosity syndrome (inc hematocrit), Plethora, Itching after hot shower (inc Basophils), Erythromelalgia (microthrombi), Peptic ulcers (inc Histamine), Gout (high turnover)
- Rx: Phlebotomy or Hydroxyurea
- Ruxoli-tinib for hydroxyurea resistant cases
CML (Chronic Myeloid Leukemia)
- t(9;22) BCR-ABL mutation —> Philadelphia chromosome —> Inc tyrosine kinase activity
- Granulocytes proliferation, especially Basophils and Metamyelocytes.
- Rx: Imatinib (tyrosine kinase blocker)
- Phases are:
a. Chronic: stable phase
b. Accelarated: When becoming symtomatic e.g. splenomegally
c. Blast: Transform into AML or ALL
Essential thrombocythemia
- JAK-2 mutation —> inc platelets —> overfunction can cause thrombosis or under function can cause bleeding.